BRCA or PALB2-mutant pancreatic ductal adenocarcinoma

What changed: BRCA or PALB2-mutant pancreatic ductal adenocarcinoma

Cancer page →

Every dated change on the records linked to BRCA or PALB2-mutant pancreatic ductal adenocarcinoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.

Trial result3Milestone6This record1

FollowWatch this cancer and Saved shows what changed since you last looked.Follow by feed

September 2026 · 1

2026-09-18This recordBRCA or PALB2-mutant pancreatic ductal adenocarcinoma
Facts on this page last checked
When this page itself was last checked or edited.

2022 · 1

2022Trial resultPREOPANC-1 / PREOPANC-2
PREOPANC-1 / PREOPANC-2 reported
PREOPANC-1 5-year OS 20.

2021 · 1

2021MilestoneRucaparib
Rucaparib maintenance phase 2 extends the approach to PALB2 and somatic alterations
A milestone in how this cancer is treated.

2019 · 2

2018 · 2

2014 · 1

2014MilestonePlatinum-sensitive / platinum-resistant
Retrospective series show BRCA carriers with pancreatic cancer live longer on platinum chemotherapy
A milestone in how this cancer is treated.

2005 · 1

2005MilestonePARP inhibitors
PARP inhibition shown to kill BRCA-deficient cells (synthetic lethality)
A milestone in how this cancer is treated.

1994 · 1

1994MilestoneBRCA1 / BRCA2 (HRD)
BRCA1 identified; BRCA2 follows in 1995 and is linked to pancreatic cancer risk
A milestone in how this cancer is treated.